Prospective study of predictor for efficiency of treatment with Nintedanib for idiopathic pulmonary fibrosis
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Biomarker; Therapeutic Use
- 08 Oct 2017 Planned End Date changed from 30 Sep 2018 to 31 Mar 2019.
- 27 Sep 2016 Planned End Date changed from 30 Sep 2017 to 30 Sep 2018.
- 18 Nov 2015 New trial record